JP MORGAN/CALL/ELI LILLY & CO/1290/0.01/19.12.25 | Market Closed - Börse Stuttgart 09:59:03 22/05/2024 BST | ||
| 0.42 EUR | 0.00% |
|
| Current month | +7.69% | ||
| 1 month | +40.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 0.42 | 0.00% |
| 21/05/24 | 0.42 | +31.25% |
| 20/05/24 | 0.32 | -3.03% |
| 17/05/24 | 0.33 | -10.81% |
| 16/05/24 | 0.37 | +23.33% |
Delayed Quote Börse Stuttgart
Last update May 22, 2024 at 09:59 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK6ZHX |
| ISIN | DE000JK6ZHX7 |
| Date issued | 10/04/2024 |
| Strike | 1,290 $ |
| Maturity | 19/12/2025 (576 Days) |
| Parity | 100 : 1 |
| Emission price | 0.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.42 € |
|---|---|
| Lowest since issue | 0.26 € |
| Spread | 0.03 € |
| Spread % | 6.67% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.4
USD
Spread / Average Target
+5.92%
- Stock Market
- Warrants
- Warrant
